| [1] |
Francis A，Harhay MN，Ong ACM，et al. Chronic kidney disease and the global public health agenda： an international consensus [J]. Nat Rev Nephrol，2024，20（7）：473-485.
|
| [2] |
Zoccali C，Mark PB，Sarafidis P，et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease[J]. Nat Rev Nephrol，2023，19（11）：733-746.
|
| [3] |
Matsushita K，Ballew SH，Wang AY，et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease [J]. Nat Rev Nephrol，2022，18（11）：696-707.
|
| [4] |
Quiroga B，Díez J. Estimation of glomerular filtration rate in cardiorenal patients： a step forward [J]. Clin Kidney J，2023，16（7）：1049-1055.
|
| [5] |
Huerta A，López B，Ravassa S，et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients： potential role of altered collagen metabolism [J]. J Hypertens，2016，34（1）：130-138.
|
| [6] |
Shen Y，Zhang X，Li C，et al. Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy [J]. Ann Transl Med，2020，8（22）：1514.
|
| [7] |
Jung E，Ro YS，Ryu HH，et al. Cystatin C and mortality risk in the general population： systematic review and dose response meta-analysis [J]. Biomarkers，2022，27（3）：222-229.
|
| [8] |
Lv Z，Fu Y，Liu C，et al. The role of cardiac remodeling associated with renal function in mediating cardiovascular event outcomes [J]. iScience，2024，27（3）：109143.
|
| [9] |
Mizdrak M，Kumric M，Kurir TT，et al. Emerging biomarkers for early detection of chronic kidney disease [J]. J Pers Med，2022，12（4）：548.
|
| [10] |
Yang HH，Wang X，Li S，et al. Lipocalin family proteins and their diverse roles in cardiovascular disease [J]. Pharmacol Ther，2023，244：108385.
|
| [11] |
Gu Y，Sun W，Xu ZH，et al. Neutrophil gelatinase-associated lipocalin 2 accelerates hypoxia-induced endothelial cell injury via eNOS/NRF2 signalling [J]. Cell J，2021，23（4）：435-444.
|
| [12] |
Hasegawa M，Ishii J，Kitagawa F，et al. Plasma neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease [J]. Biomed Res Int，2016，2016：8761475.
|
| [13] |
Song X，Cai D，Zhang B. Clinical values of serum NGAL combined with NT-proBNP in the early prognosis of type 1 cardiorenal syndrome [J]. Am J Transl Res，2021，13（4）：3363-3368.
|
| [14] |
Kim IY，Kim JH，Kim MJ，et al. Plasma neutrophil gelatinaseassociated lipocalin is independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease [J]. PLoS One，2018，13（10）：e0205848.
|
| [15] |
Wybraniec MT，Chudek J，Mizia-Stec K. Association between elevated urinary levels of kidney injury molecule type 1 and adverse cardiovascular events at 12 months in patients with coronary artery disease [J]. Pol Arch Intern Med，2018，128（5）：301-309.
|
| [16] |
Feldreich T，Nowak C，Fall T，et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease[J]. J Nephrol，2019，32（1）：111-119.
|
| [17] |
Park M，Hsu CY，Go AS，et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death：the CRIC study [J]. Clin J Am Soc Nephrol，2017，12（5）：761-771.
|
| [18] |
McMillan R，Skiadopoulos L，Hoppensteadt D，et al. Biomarkers of endothelial，renal，and platelet dysfunction in stage 5 chronic kidney disease hemodialysis patients with heart failure [J]. Clin Appl Thromb Hemost，2018，24（2）：235-240.
|
| [19] |
Kaplan P，Tatarkova Z，Sivonova MK，et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems [J].Int J Mol Sci，2020，21（20）：7698.
|
| [20] |
Spence JD，Urquhart BL. Cerebrovascular disease，cardiovascular disease，and chronic kidney disease：interplays and influences [J].Curr Neurol Neurosci Rep，2022，22（11）：757-766.
|
| [21] |
Ding C，Li J，Wei Y，et al. Associations of total homocysteine and kidney function with all-cause and cause-specific mortality in hypertensive patients： a mediation and joint analysis [J].Hypertens Res，2024，47（6）：1500-1511.
|
| [22] |
ALSolami AA，Almalki AA，Alhedyan SY，et al. Plasma homocysteine levels and cardiovascular events in patients with end-stage renal disease： a systematic review [J]. Cureus，2023，15（6）： e40357.
|
| [23] |
Tang Y，Liu T，Sun S，et al. Role and mechanism of growth differentiation factor 15 in chronic kidney disease [J]. J Inflamm Res，2024，17：2861-2871.
|
| [24] |
Ding C，Li J，Wei Y，et al. Associations of total homocysteine and kidney function with all-cause and cause-specific mortality in hypertensive patients： a mediation and joint analysis [J].Hypertens Res，2024，47（6）：1500-1511.
|
| [25] |
Kobayashi S，Yamazaki H，Imamura T，et al. Implication of serum growth differentiation factor-15 level in patients with renal diseases [J]. Int Urol Nephrol，2023，55（11）：2935-2941.
|
| [26] |
Lidgard B，Zelnickv L，Anderson AH，et al. Cardiac biomarkers and risk of atherosclerotic cardiovascular disease in patients with CKD [J]. Kidney360，2022，3（5）：859-871.
|
| [27] |
Claus R，Berliner D，Bavendiek U，et al. Soluble neprilysin，NT-proBNP，and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients（SONGBIRD） [J]. Clin Res Cardiol，2020，109（8）：1035-1047.
|
| [28] |
Kato ET，Morrow DA，Guo J，et al. Growth differentiation factor 15 and cardiovascular risk：individual patient meta-analysis[J].Eur Heart J，2023，44（4）：293-300.
|
| [29] |
Eggers KM，Batra G，Lindahl B，et al. Temporal biomarker concentration patterns during the early course of acute coronary syndrome [J]. Clin Chem Lab Med，2024，62（6）：1167-1176.
|
| [30] |
Alam ML，Katz R，Bellovich KA，et al. Soluble ST2 and galectin-3 and progression of CKD [J]. Kidney Int Rep，2018，4（1）：103-111.
|
| [31] |
Hara A，Niwa M，Noguchi K，et al. Galectin-3 as a nextgeneration biomarker for detecting early stage of various diseases[J]. Biomolecules，2020，10（3）：389.
|
| [32] |
Tummalapalli SL，Zelnick LR，Andersen AH，et al. Association of cardiac biomarkers with the Kansas city cardiomyopathy questionnaire in patients with chronic kidney disease without heart failure [J]. J Am Heart Assoc，2020，9（13）： e014385.
|
| [33] |
Han X，Zhang S，Chen Z，et al. Cardiac biomarkers of heart failure in chronic kidney disease [J]. Clin Chim Acta，2020，510：298-310.
|
| [34] |
Liu S，Wu Q，Zhang S，et al. Serum galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients：a prospective cohort study [J]. BMC Nephrol，2022，23（1）：5.
|
| [35] |
Bayes-Genis A，Zamora E，de Antonio M，et al. Soluble ST2 serum concentration and renal function in heart failure [J]. J Card Fail，2013，19（11）：768-775.
|
| [36] |
Tuegel C，Katz R，Alam M，et al. GDF-15，galectin 3，soluble ST2，and risk of mortality and cardiovascular events in CKD[J]. Am J Kidney Dis，2018，72（4）：519-528.
|
| [37] |
Filipska I，Winiarska A，Knysak M，et al. Contribution of gut microbiota-derived uremic toxins to the cardiovascular system mineralization [J]. Toxins （Basel），2021，13（4）：274.
|
| [38] |
Lim YJ，Sidor NA，Tonial NC，et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease：mechanisms and therapeutic targets[J]. Toxins（Basel），2021，13（2）：142.
|
| [39] |
Jing YJ，Ni JW，Ding FH，et al. p-Cresyl sulfate is associated with carotid arteriosclerosis in hemodialysis patients and promotes atherogenesis in ApoE-/-mice [J]. Kidney Int，2016，89（2）：439-449.
|
| [40] |
Hsu CC，Lu YC，Chiu CA，et al. Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis [J]. Clin Invest Med，2013，36（1）： E42-E49.
|
| [41] |
Li Q，Zhang S，Wu QJ，et al. Serum total indoxyl sulfate levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients： a prospective cohort study [J]. BMC Nephrol，2022，23（1）：231.
|
| [42] |
Nemet I，Saha PP，Gupta N，et al. A cardiovascular diseaselinked gut microbial metabolite acts via adrenergic receptors[J].Cell，2020，180（5）：862-877.
|
| [43] |
Zhang Z，Cai B，Sun Y，et al. Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure [J]. Front Cardiovasc Med，2023，9：1076806.
|
| [44] |
Poesen R，Claes K，Evenepoel P，et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD [J]. J Am Soc Nephrol，2016，27（11）：3479-3487.
|
| [45] |
Zhang Y，Wang Y，Ke B，et al. TMAO： how gut microbiota contributes to heart failure [J]. Transl Res，2021，228：109-125.
|
| [46] |
Gencer B，Li XS，Gurmu Y，et al. Gut microbiota-dependent trimethylamine N-oxide and cardiovascular outcomes in patients with prior myocardial infarction： a nested case control study from the PEGASUS-TIMI 54 trial [J]. J Am Heart Assoc，2020，9（10）： e015331.
|
| [47] |
Shafi T，Powe NR，Meyer TW，et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients[J]. J Am Soc Nephrol，2017，28（1）：321-331.
|
| [48] |
Stubbs JR，Stedman MR，Liu S，et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis [J]. Clin J Am Soc Nephrol，2019，14（2）：261-267.
|
| [49] |
Genoni A，Christophersen CT，Lo J，et al. Long-term paleolithic diet is associated with lower resistant starch intake，different gut microbiota composition and increased serum TMAO concentrations[J]. Eur J Nutr，2019，59（5）：1845-1858.
|
| [50] |
Yamada S，Nakano T. Role of chronic kidney disease （CKD）-mineral and bone disorder （MBD） in the pathogenesis of cardiovascular disease in CKD [J]. J Atheroscler Thromb，2023，30（8）：835-850.
|
| [51] |
Kandarini Y，Mahadita GW，Herawati S，et al. High C-terminal fibroblast growth factor-23，intact parathyroid hormone，and interleukin-6 as determinants of valvular calcification in regular hemodialysis patients [J]. Int J Gen Med，2022，15：4227-4236.
|
| [52] |
Epstein M，Freundlich M. The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade： a duopoly that promotes renal and cardiovascular injury [J]. Nephrol Dial Transplant，2022，37（2）：211-221.
|
| [53] |
Yang K，Yang J，Bi X，et al. Serum Klotho，cardiovascular events，and mortality in nondiabetic chronic kidney disease [J].Cardiorenal Med，2020，10（3）：175-187.
|
| [54] |
Silva AP，Mendes F，Carias E，et al. Plasmatic klotho and FGF23 levels as biomarkers of CKD-associated cardiac disease in type 2 diabetic patients [J]. Int J Mol Sci，2019，20（7）：1536.
|